More than rare earth, 96.6% of material for US antibotics pencilin come from China


AssassinsMace

Brigadier
Bad quality Chinese penicillin has traces of mold in it. ;)

The US has the highest prices for pharmaceuticals in the world and they outsource the manufacture of it. They going to claim China is stealing the US blind from there too. Is Martin Shkreli Chinese?
 

FriedRiceNSpice

Senior Member
And Western pharmas make patented drugs using cheap Chinese APIs and sells it back to China for hundreds of dollars per dose. All the while the West complain about China not respecting patents and intellectual property! Another case of Western liberal media only picking out only the details that support it's own narrative and ignoring rest of the facts. Also a good example of the vaunted intellectual property rights that the West makes such a big deal about protecting.
 

Jura

General
one more googlefu link, this time to
January 9, 2019
Exposing the Risks of America's Dependence on China for Medicine
Please, Log in or Register to view URLs content!


and I leave the topic because in the meantime I recalled as a small kid I often had had
Please, Log in or Register to view URLs content!

so at one point I got a shot of what they called Pendepon (yeah I still remember the name): if I'm not mistaken, 0.1 liter of penicillin solution intramuscularly

LOL now but it hurt as Hell
 

Hendrik_2000

Brigadier
Not only just generic drug China now beat their competitor in Cancer drug too
Excerpt from bloomberg
China’s Churning Out Revolutionary Cancer Drugs Much Cheaper Than the U.S.
Please, Log in or Register to view URLs content!

One way to realize Beijing’s dreams of a world-class pharmaceutical industry: low prices.

Bloomberg News
June 4, 2019, 2:00 PM CDT Updated on June 5, 2019, 9:36 AM CDT

ILLUSTRATION: EVA CREMERS FOR BLOOMBERG BUSINESSWEEK
Western companies last year began selling some of their hottest cancer drugs, called PD-1 inhibitors, with much fanfare in China. But rather than quickly conquering the mainland market, American drugmakers
Please, Log in or Register to view URLs content!
and
Please, Log in or Register to view URLs content!
have found themselves facing a surprising challenge: local competitors. Chinese companies are introducing patented cancer therapies in their home market based on PD-1 inhibitors, which use the body’s immune system to fight tumors. They’re doing it at far lower prices—sometimes a third of what U.S. drugmakers charge—which will likely give them a leg up at home. And their ambitions go far beyond the mainland, with several already preparing to sell their medicines in the U.S. and worldwide.

The push into PD-1 drugs marks one of the first forays by China’s pharmaceutical industry into complex treatments. It’s the coming of age for a local industry long focused on cheap generics and chemical ingredients, and it’s being aided by Beijing’s efforts to speed up drug approvals and channel more funding toward health care.

Developing a world-class pharmaceutical business is a priority for China’s leaders. Beijing’s Made in China 2025 plan identifies the drug industry as one of 10 sectors—along with aviation, electric vehicles, and advanced rail equipment—in which China will look for technological breakthroughs.

One way Chinese companies plan to elbow into the market is lower pricing.
Please, Log in or Register to view URLs content!
began selling its drug, called Tuoyi in China, in December for 187,000 yuan ($27,105) for a year’s dose for melanoma, a skin cancer. That’s one-third the cost of using Merck’s Keytruda in China for the same condition over the same period, according to data compiled by
Please, Log in or Register to view URLs content!
Junshi is conducting clinical trials to enter the U.S. market. (Merck does business as Merck Sharp & Dohme, or MSD, outside the U.S. and Canada.)


Chinese companies say their medicines are structurally different from what American companies offer. “We are very confident in our own patent around the world,” says Wu Xiaobin, president of Beijing-based
Please, Log in or Register to view URLs content!
, which has filed for approval for its PD-1 drug in China while it continues its international clinical trials, including in the U.S. “We have been well prepared on this because we’ve always planned to go global.”

Jiangsu-based
Please, Log in or Register to view URLs content!
, which also sells a PD-1 therapy in China that’s cheaper than the two foreign brands, has a licensing agreement with
Please, Log in or Register to view URLs content!
through which the U.S. pharma giant will also be responsible for clinical trials, further development work, and marketing the medicine overseas.

Other Chinese biotechnology companies are also preparing to enter local and overseas markets.
Please, Log in or Register to view URLs content!
, one of China’s biggest drugmakers, on May 31 said its PD-1 drug had received Chinese regulatory approval. “PD-1s are at the cutting edge of science and are transforming cancer care,” says Brad Loncar, a biotech investor and chief executive officer at Loncar Investments in Lenexa, Kan. So the push by Chinese companies into these drugs won’t just “transform care in China but also have global implications,” he says.

Foreign companies are looking to license Chinese drugs globally, says Lin Lijun, founder of Shanghai-based
Please, Log in or Register to view URLs content!
, which invests in Chinese biotech companies including Junshi. China’s health industry has benefited from increased funding and local scientists returning home after gaining experience overseas. Also, many new medicines made by local and foreign companies are now approved in a fraction of the time the process once took.

China is new to developing innovative drugs, so managing their safety and efficacy remains a risk, says Zhang Jialin, an analyst with
Please, Log in or Register to view URLs content!
. Chinese companies say their trials show their medicines are safe, and some are following up with larger studies.

Projected Market Size of PD-1 and PD-L1 Antibody Drugs
 

Tam

Major
Registered Member
India also makes some drugs too. Blood pressure meds like the one I take --- and which the FDA has recently made recalls --- are made in two plants, one in China and one in India, with the problem samples containing trace quantities of a potential carcinogenic, coming from both. The problem arose with a recent change in the production process. Of course I am concerned.
 

Jura

General
now I read
Will China use antibiotics against US amid trade war?
Source:Global Times Published: 2019/9/10 21:58:40
Please, Log in or Register to view URLs content!

China has more than just rare-earth minerals to rely on amid the trade war with the US - it also has antibiotics, according to recent media reports.

It is understandable that China's dominance in antibiotics has made some observers uneasy amid the trade tensions. However, there is little chance that China will weaponize antibiotics to fight back against US tariffs.

A fragile supply chain of antibiotics in the US complicates US relations with China. Gary Cohn, the former top economic adviser to Donald Trump, has warned the president that China produces 96.6 percent of the antibiotics used in the US, according to an article on UK newspaper the Sun's website.

China is now the world's only source of some key ingredients for antibiotics. This makes some US officials aware of the seriousness of the situation. Cohn has "asked Trump what he would tell mothers when their babies were dying of strep throat because the US does not produce penicillin," the Sun's article said.

China is reportedly the world's largest exporter of ingredients for antibiotics and vitamins. Li Daokui, a leading macroeconomist from Tsinghua University, said in March that medical systems in some developed countries would not function well if China reduces its exports of those ingredients. The words have been seen as a signal that China may curb its exports of antibiotics as a countermeasure in trade tensions with the US.

The market has perhaps read too much into Li's words. Antibiotics are a trump card for China, but there is little possibility that Beijing will use it to fight back against the US.

China will try its best to prevent a trade war with the US from harming innocent American patients and causing casualties. China has various tools that it can deploy to hit back against the US, such as rare-earth minerals and US Treasuries. There's no need to rely on antibiotics.

However, the US-launched trade war has a direct impact on the supply chains between China and the US. Even if Beijing has no intention of weaponizing antibiotics, trade tensions may lead to a rise in prices of antibiotics in the US market, and American people will have to pay the price.
 

Tam

Major
Registered Member
No need to weaponize rare earths, antibiotics and even Christian Bibles (most of these are printed in China) for any trade war, Tariff Man Trump will and has put a tariff on them anyway and will further raise them up by December.
 

Top